Back
Harmony Biosciences Holdings Inc (HRMY)
PharmaceuticalsHRMY · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$38.14
+0.13%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$2.71
ROE
17.9%
Gross margin
76.5%
Debt/Equity
0.18x
Revenue growth
16.6%
Harmony Biosciences Holdings Inc — company intelligence
Earnings surprises
Q2 2026$1.28 vs $1.04 est+23.3%
Q1 2026$0.55 vs $0.71 est-22.3%
Q4 2025$0.38 vs $0.91 est-58.4%
Q3 2025$0.87 vs $0.86 est+1.6%
Analyst consensus · 16 analysts
11 Buy4 Hold1 Sell
Updated Aug 20, 2026
Recent SEC filings
8-K — Material event reportAug 4, 2026
10-Q — Quarterly reportAug 4, 2026
8-K — Material event reportJul 16, 2026
Latest news
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) — SeekingAlpha · 1w ago
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline — Yahoo · 1w ago
Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript — Yahoo · 2w ago
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge — Yahoo · 2w ago
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.